Merck’s Fast-Ascending Kidney Cancer Drug Hits a Setback

Why It Matters

The failure limits Merck’s ability to replace Keytruda revenue and reshapes the competitive landscape in kidney‑cancer therapy, opening a market gap for rivals like Arcus.

Key Takeaways

• Welireg’s first‑line combo missed primary survival endpoints
• Merck’s projected $5.8 billion first‑line revenue now off the table
• Arcus Biosciences eyes first‑line HIF‑2α trial after Welireg setback
• Merck shares dropped ~4 % on trial disappointment

Pulse Analysis

Merck’s recent Phase 3 trial disappointment underscores the high stakes of expanding oncology portfolios beyond blockbuster immunotherapies. Welireg, a HIF‑2α inhibitor acquired from Peloton Therapeutics, has been a cornerstone of Merck’s strategy to mitigate the looming revenue gap from Keytruda’s patent cliff. While the drug showed robust growth in 2025—$716 million in sales and a 40 % year‑over‑year increase—its inability to demonstrate a meaningful benefit in the first‑line setting erodes the projected $5.8 billion revenue stream that analysts had tied to a successful label expansion.

The broader implication for the kidney‑cancer market is a potential reshuffling of therapeutic leadership. Arcus Biosciences, which is developing a rival HIF‑2α inhibitor called casdatifan, plans to launch a Phase 3 first‑line trial later this year. Without the toxicity of a tyrosine‑kinase inhibitor like Lenvima, Arcus’s regimen could appeal to clinicians seeking a cleaner safety profile. Market observers see this as a "potential opening" for Arcus, especially as Merck’s Litespark program continues to explore other combinations that may still succeed.

For investors and industry watchers, the episode highlights the volatility inherent in oncology drug development, where a single trial can swing expectations for multi‑billion‑dollar revenue streams. Merck must now rely on its remaining Welireg studies and alternative pipelines to sustain growth, while competitors accelerate their own HIF‑2α programs. The outcome will shape not only Merck’s financial trajectory but also the therapeutic options available to patients with clear‑cell renal cell carcinoma.